MedTrace Logo

Volatile Organic Compounds for the Assessment of Liver Disease

NCT04620538 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2026-03-30

No results posted yet for this study

Summary

This study aims to determine whether a breath test could be used for early detection of hepatic fibrosis, cirrhosis or hepatocellular carcinoma.

Patients who are attending for a planned liver outpatient services or investigations will be approached to provide a breath sample.

Multi platform mass spectrometry analysis will be performed to establish volatile biomarkers that can discriminate between fibrosis, cirrhosis and hepatocellular carcinoma.

Conditions

Interventions

DIAGNOSTIC_TEST

Breath Analysis

Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • George B Hanna, FRCS · Imperial College London

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2026-03-25
Completion
2026-03-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04620538 on ClinicalTrials.gov